Market revenue in 2023 | USD 67.7 million |
Market revenue in 2030 | USD 128.5 million |
Growth rate | 9.6% (CAGR from 2023 to 2030) |
Largest segment | Contract manufacturing |
Fastest growing segment | Contract Development |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Contract Manufacturing, Contract Development |
Key market players worldwide | Eurofins Scientific SE, WuXi Biologics (Cayman) Inc, Catalent Inc, AGC Inc, Siegfried Holding AG, Boehringer Ingelheim, FUJIFILM Holdings Corp, Samsung BioLogics, Rentschler Biopharma SE, Recipharm |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to large molecule drug substance cdmo market will help companies and investors design strategic landscapes.
Contract manufacturing was the largest segment with a revenue share of 67.06% in 2023. Horizon Databook has segmented the Brazil large molecule drug substance cdmo market based on contract manufacturing, contract development covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil is the largest country in Latin America and is the fifth most populous in the world. It is among the countries with well-established, effective clinical trial platforms.
Brazil scientific literature output is already on par with EU countries, such as Switzerland, Sweden, Holland, and Russia. The Brazilian government has taken concrete steps to improve co-operation between universities and industry.
Another article published by Outsourcing Pharma stated that lower cost of clinical study and testing might drive the large molecule drug substance CDMO market in the country. However, regulatory issues have restrained the clinical development, which in turn, is limiting growth of CDMOs in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil large molecule drug substance cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Brazil large molecule drug substance cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account